{
   "title": "Pharma company ranking based on R & D for developing countries 2018",
   "xAxis": "Month",
   "yAxis": "Indicator score from 1 (lowest) to 5 (highest)",
   "columnType": "two",
   "graphType": "bar",
   "summaryType": "nlp",
   "summary": [
      "This chart shows the Indicator of score made by Month . ",
      "\\n Sanofi has the highest Indicator of score sitting at 12.8",
      "\\n Second to Sanofi is Novartis_AG at 9.2 score ."
   ],
   "trends": [
      {},
      {
         "1": "4"
      },
      {
         "3": "4",
         "5": "2"
      }
   ],
   "data": [
      {
         "Month": "GlaxoSmithKline plc",
         "Indicator score from 1 (lowest) to 5 (highest)": "4.0"
      },
      {
         "Month": "Merck KGaA",
         "Indicator score from 1 (lowest) to 5 (highest)": "3.69"
      },
      {
         "Month": "Novartis AG",
         "Indicator score from 1 (lowest) to 5 (highest)": "3.55"
      },
      {
         "Month": "Johnson & Johnson",
         "Indicator score from 1 (lowest) to 5 (highest)": "3.19"
      },
      {
         "Month": "Sanofi",
         "Indicator score from 1 (lowest) to 5 (highest)": "2.83"
      },
      {
         "Month": "Eisai Co. Ltd.",
         "Indicator score from 1 (lowest) to 5 (highest)": "2.8"
      },
      {
         "Month": "Takeda Pharmaceutical Co.",
         "Indicator score from 1 (lowest) to 5 (highest)": "2.8"
      },
      {
         "Month": "Daiichi Sankyo Co. Ltd.",
         "Indicator score from 1 (lowest) to 5 (highest)": "2.71"
      },
      {
         "Month": "Bayer AG",
         "Indicator score from 1 (lowest) to 5 (highest)": "2.14"
      },
      {
         "Month": "Novo Nordisk A/S",
         "Indicator score from 1 (lowest) to 5 (highest)": "2.09"
      },
      {
         "Month": "AstraZeneca plc",
         "Indicator score from 1 (lowest) to 5 (highest)": "2.05"
      },
      {
         "Month": "Astellas Pharma Inc.",
         "Indicator score from 1 (lowest) to 5 (highest)": "2.01"
      },
      {
         "Month": "AbbVie Inc.",
         "Indicator score from 1 (lowest) to 5 (highest)": "1.98"
      },
      {
         "Month": "Pfizer Inc.",
         "Indicator score from 1 (lowest) to 5 (highest)": "1.9"
      },
      {
         "Month": "Roche Holding Ltd",
         "Indicator score from 1 (lowest) to 5 (highest)": "1.84"
      },
      {
         "Month": "Merck & Co. Inc.",
         "Indicator score from 1 (lowest) to 5 (highest)": "1.78"
      },
      {
         "Month": "Boehringer-Ingelheim GmbH",
         "Indicator score from 1 (lowest) to 5 (highest)": "1.73"
      },
      {
         "Month": "Bristol-Myers Squibb Co.",
         "Indicator score from 1 (lowest) to 5 (highest)": "1.56"
      },
      {
         "Month": "Gilead Sciences Inc.",
         "Indicator score from 1 (lowest) to 5 (highest)": "1.43"
      },
      {
         "Month": "Eli Lilly & Co.",
         "Indicator score from 1 (lowest) to 5 (highest)": "0.88"
      }
   ],
   "gold": "This statistic depicts a pharmaceutical company ranking based on R & D for developing countries in 2018 , according to the Access to Medicine Index 2018 . In that year , the leading company concerning research and development for these markets was GlaxoSmithKline with an indicator score of four points . The Access to Medicine Index is an independent initiative that ranks the world 's 20 largest companies according to their efforts to make their products more available , affordable and accessible in developing countries , highlighting policy and practice that either facilitate or hinder access to medicine .\n"
}